BioArctic AB (publ) (BIOA-B.ST)
SEK 170.0
(-0.93%)
SEK 170.0
(-0.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.18 Billion SEK | 38.19% |
| 2022 | 858.3 Million SEK | -4.39% |
| 2021 | 897.73 Million SEK | -14.53% |
| 2020 | 1.05 Billion SEK | -11.24% |
| 2019 | 1.18 Billion SEK | -15.05% |
| 2018 | 1.39 Billion SEK | 22.14% |
| 2017 | 1.14 Billion SEK | 61.09% |
| 2016 | 707.97 Million SEK | 439.98% |
| 2015 | 131.11 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.13 Billion SEK | -0.38% |
| 2024 Q1 | 1.13 Billion SEK | -4.19% |
| 2023 Q1 | 1.15 Billion SEK | 34.56% |
| 2023 Q4 | 1.18 Billion SEK | -4.52% |
| 2023 FY | 1.18 Billion SEK | 38.19% |
| 2023 Q3 | 1.24 Billion SEK | 14.33% |
| 2023 Q2 | 1.08 Billion SEK | -5.92% |
| 2022 Q2 | 794.58 Million SEK | -6.17% |
| 2022 Q1 | 846.8 Million SEK | -5.67% |
| 2022 Q4 | 858.3 Million SEK | -5.22% |
| 2022 Q3 | 905.57 Million SEK | 13.97% |
| 2022 FY | 858.3 Million SEK | -4.39% |
| 2021 FY | 897.73 Million SEK | -14.53% |
| 2021 Q1 | 1 Billion SEK | -4.22% |
| 2021 Q3 | 935.22 Million SEK | -3.93% |
| 2021 Q2 | 973.48 Million SEK | -3.23% |
| 2021 Q4 | 897.73 Million SEK | -4.01% |
| 2020 Q2 | 1.09 Billion SEK | -3.74% |
| 2020 FY | 1.05 Billion SEK | -11.24% |
| 2020 Q4 | 1.05 Billion SEK | -2.4% |
| 2020 Q3 | 1.07 Billion SEK | -2.16% |
| 2020 Q1 | 1.14 Billion SEK | -3.45% |
| 2019 Q3 | 1.23 Billion SEK | -2.8% |
| 2019 Q4 | 1.18 Billion SEK | -4.54% |
| 2019 FY | 1.18 Billion SEK | -15.05% |
| 2019 Q1 | 1.31 Billion SEK | -5.64% |
| 2019 Q2 | 1.27 Billion SEK | -2.98% |
| 2018 Q4 | 1.39 Billion SEK | 34.95% |
| 2018 Q3 | 1.03 Billion SEK | -2.96% |
| 2018 FY | 1.39 Billion SEK | 22.14% |
| 2018 Q1 | 1.1 Billion SEK | -2.79% |
| 2018 Q2 | 1.06 Billion SEK | -4.05% |
| 2017 Q3 | 610.92 Million SEK | -4.36% |
| 2017 Q4 | 1.14 Billion SEK | 86.68% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 FY | 1.14 Billion SEK | 61.09% |
| 2017 Q2 | 638.79 Million SEK | 0.0% |
| 2016 Q4 | 707.97 Million SEK | 0.0% |
| 2016 FY | 707.97 Million SEK | 439.98% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | 131.11 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -901.332% |
| Ziccum AB (publ) | 14.97 Million SEK | -7821.974% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -5818.258% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -1801.467% |
| Mendus AB (publ) | 755.95 Million SEK | -56.899% |
| Genovis AB (publ.) | 288.85 Million SEK | -310.611% |
| Intervacc AB (publ) | 259.61 Million SEK | -356.867% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -2726.755% |
| Active Biotech AB (publ) | 44 Million SEK | -2595.632% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -325.506% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -1808.35% |
| Aptahem AB (publ) | 63.02 Million SEK | -1781.918% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -139.009% |
| Kancera AB (publ) | 65.64 Million SEK | -1706.861% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -237.593% |
| Fluicell AB (publ) | 9.34 Million SEK | -12598.908% |
| Saniona AB (publ) | 64.14 Million SEK | -1749.115% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -3429.784% |
| Biovica International AB (publ) | 131.4 Million SEK | -802.592% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -2138.517% |
| AcouSort AB (publ) | 34.51 Million SEK | -3336.612% |
| Xintela AB (publ) | 18.39 Million SEK | -6347.828% |
| Abliva AB (publ) | 87.49 Million SEK | -1255.533% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | -56.022% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 5.747% |
| OncoZenge AB (publ) | 20.34 Million SEK | -5731.259% |
| Amniotics AB (publ) | 26.08 Million SEK | -4446.799% |
| 2cureX AB (publ) | 16.62 Million SEK | -7034.304% |
| CombiGene AB (publ) | 120.61 Million SEK | -883.383% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -19417.492% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 37.593% |
| Camurus AB (publ) | 1.9 Billion SEK | 37.831% |
| Corline Biomedical AB | 100.1 Million SEK | -1084.834% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -569.643% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -743.601% |
| I-Tech AB | 152.44 Million SEK | -678.047% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | -16.506% |
| Cyxone AB (publ) | 43.65 Million SEK | -2616.935% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -1407.241% |
| Biosergen AB | 7.2 Million SEK | -16371.018% |
| Cantargia AB (publ) | 223.71 Million SEK | -430.181% |
| NextCell Pharma AB | 81.28 Million SEK | -1359.106% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | -54.99% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -3830.921% |
| Nanologica AB (publ) | 77.42 Million SEK | -1431.827% |
| SynAct Pharma AB | 228.01 Million SEK | -420.166% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -4331.783% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -5365.073% |
| LIDDS AB (publ) | 17.65 Million SEK | -6618.086% |
| Lipum AB (publ) | 12.11 Million SEK | -9694.203% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 15.291% |
| Alzinova AB (publ) | 123.18 Million SEK | -862.812% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -397.562% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -13928.125% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -1291.669% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -7876.851% |
| Simris Alg AB (publ) | 174.55 Million SEK | -579.498% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -446.484% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -81.494% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -1262.181% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -4060.509% |